The upsized ATM facility adds overhang and signals continued cash burn ahead of Phase 3 data in mid-2027. Monitor daily volume and price action for signs of accelerated selling; the stock may face persistent downward pressure as the ATM is utilized.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $31.67entry
- T+1 · 3mo ago +0.82%α +1.02% · $31.93
- T+5 · 3mo ago +4.07%α +4.17% · $32.96
- T+20 · 3mo ago −2.46%α −1.22% · $30.89
- T+60 · 20d ago −17.49%α −17.28% · $26.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Stoke Therapeutics filed a 424B5 prospectus supplement to upsize its at-the-market (ATM) equity offering facility from $150M to $200M, replacing the prior March 2026 supplement. The company has already raised $146.4M in net proceeds from prior sales under the same Cantor Fitzgerald agreement. This filing signals ongoing dilution risk for existing shareholders, with new investors facing immediate dilution of $21.05 per share at the current price of $28.86.
Key Facts
- Stoke upsized its ATM offering to up to $200,000,000 in aggregate common stock sales, replacing the prior $150M facility.
- The company has already sold ~4.7 million shares for aggregate net proceeds of $146.4 million under the prior supplement.
- At the assumed offering price of $28.86 per share, new investors would incur immediate dilution of $21.05 per share.
- Proceeds are earmarked for general corporate purposes including R&D, clinical development, and commercialization preparations.
- Cantor Fitzgerald will receive up to 3.0% commission on gross proceeds as sales agent.
Financial Impact
Up to $200M in potential new equity issuance; $146.4M already raised under prior facility. New investors face $21.05/share dilution at $28.86 offering price.
Risk Factors
- Continued dilution from ATM sales could pressure the stock price.
- No minimum offering amount, the company may sell shares opportunistically at any price.
- High short interest (~25.2% of float) amplifies downside risk if selling accelerates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-330792 |
| Document: d137193dexfilingfees.htm | 0001193125-26-330792 |
| Document: 0001193125-26-330792-index-headers.html | 0001193125-26-330792 |
| Document: 0001193125-26-330792-index.html | 0001193125-26-330792 |
| Document: 0001193125-26-330792.txt | 0001193125-26-330792 |
Track record
18 reports on STOK
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.49% at T+60 after the Aug 3, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $27.02 Now $26.63 −1.44% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $26.12 Now $26.63 +1.95% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $26.07 Now $26.63 +2.15% settles Feb 3
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $26.29 Now $26.63 +1.29% settles Jan 28
- Oct 21, 202626d ago 144 Bearish 6/10 Entry $25.70 Now $26.63 −3.62% settles Jan 20
- Sep 30, 20266w ago SC 13G Neutral 4/10 Entry $26.01 Now $26.63 +2.38% settles Dec 28
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $25.50 Now $26.63 +4.43% settles Dec 22
- Aug 18, 202612w ago Insider Cluster Neutral 3/10 Entry $33.03 to $26.20 Now $26.63 −19.38% ▼ −20.68% −19.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers